The EGFR-specific antibodies cetuximab and panitumumab have been widely used in the treatment of EGFR-expressing and KRAS wild-type colorectal cancer; and the HER2-targeting antibody trastuzumab has been successful in improving the outcomes of patients with HER2-expressing breast cancer (4,5,7). Here, EGFR is linked to colorectal cancer.